Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma | Zendy

Constantine S. Tam | Zendy; Mary Ann Anderson | Zendy; Christiane Pott | Zendy; Rishu Agarwal | Zendy; Sasanka M. Handunnetti | Zendy; Rodney J. Hicks | Zendy; Kate Burbury | Zendy; Gillian Turner | Zendy; Juliana Di Iulio | Zendy; Mathias Bressel | Zendy; David Westerman | Zendy; Stephen Lade | Zendy; Martin Dreyling | Zendy; SarahJane Dawson | Zendy; Mark A. Dawson | Zendy; John F. Seymour | Zendy; Andrew W. Roberts | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

Author(s) -

Constantine S. Tam,

Mary Ann Anderson,

Christiane Pott,

Rishu Agarwal,

Sasanka M. Handunnetti,

Rodney J. Hicks,

Kate Burbury,

Gillian Turner,

Juliana Di Iulio,

Mathias Bressel,

David Westerman,

Stephen Lade,

Martin Dreyling,

SarahJane Dawson,

Mark A. Dawson,

John F. Seymour,

Andrew W. Roberts

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1715519

Subject(s) - ibrutinib , mantle cell lymphoma , venetoclax , medicine , oncology , minimal residual disease , adverse effect , lymphoma , gastroenterology , bone marrow , leukemia , chronic lymphocytic leukemia

Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy. Preclinical models predict synergy in combination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research